European dimension Sample Clauses

European dimension. One of the issues driving the proactive initiative on Global Computing is the ubiquity and sheer scale of the infrastructure that must be developed to support truly dynamic and mobile computation. The problems that arise, and the solutions to be found, will inevitably reach beyond national considerations. The values and benefits anticipated in the vision of mobile computational entities can only be realised if the technology and standards used have sufficiently wide scope. A col- lection of distinct islands separated by incompatible protocols will hinder this: it is essential that research in this area involve international collaboration, and be disseminated to an in- ternational audience.
Sample 1Sample 2
AutoNDA by SimpleDocs
European dimension. This project aims at clustering different ongoing activities in several EU countries by reducing their overlapping in favour of com plementarities of strengths. Joining forces and acquiring competencies from other sectors of research, energy efficient technology sector can benefit through enforced exchange of know-how and ge nerating cross-disciplinary results. A proactive dialogue can result in new syne rgies when different competences allow new promising technological solutions. Research centres (two research centres and one university) and industries (5 SME participants) from 4 Europe an Union countries) are involved in carrying out this project, thereby guaranteeing a transnational character. It is important to bring technology suppliers and end users from different Member States toge ther to ensure that all available know-how is mobilized. Teamed toge ther, they can develop the desired outcomes. However, they do not posses the specific know-how – notably on high efficiency Stirling heat pump technology – which is obviously the core part of the project. The proposers believe that this approach is vital to ensure that the developed energy efficient technology will create confidence among the residential and commercial sectors industry in the whole Europe and will assure that the results will accommodate the needs and requirements of the future customers. Moreover, development without pan-European cooperation would imply a considerably longe r time-to-market and a risk too high to take for an individual partner. For these reasons, specific targeted research across Europe is important to achieve a cri tical mass in terms of specific knowledge required, as well as to boost RTD.
Sample 1
European dimension. ‌ The project lies at the intersection between complexity, formal checking and compilers, requiring a complex synergy between experts of the three fields, and providing an original forum for a radical interdisciplinary exploration of complexity issues from a computer assisted viewpoint. It is clear that having a geographically distributed team always poses additional problems with respect to a tightly integrated one. However, due to the dimension of the project and its visionary nature it is difficult to imagine a single agency to carry out the work. Even worse, in this case, due to the cost of the project, the results of the work would presumably be covered by copyright, and the software would hardly be open source, to the detriment of the diffusion of scientific knowledge of a foundational nature, and the industrial take up of innovative research results, that should be among the main goals of the European Union8.
Sample 1

Related to European dimension

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order.

  • Design Development Phase INDICATE IN STATEMENT OF WORK “NOT APPLICABLE” IF SECTION IS NOT APPLICABLE

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Start-Up and Synchronization Consistent with the mutually acceptable procedures of the Developer and Connecting Transmission Owner, the Developer is responsible for the proper synchronization of the Large Generating Facility to the New York State Transmission System in accordance with NYISO and Connecting Transmission Owner procedures and requirements.

  • Development Area 10.4. The Development Area shall encompass all Deposits to be produced.

  • Joint Occupational Health and Safety Committee The Employer and the Union recognize the role of the joint Occupational Health and Safety Committee in promoting a safe and healthful workplace. The parties agree that a Joint Occupational Health and Safety Committee shall be established for each Employer covered by this Collective Agreement. The Committee shall govern itself in accordance with the provisions of the Industrial Health and Safety Regulations made pursuant to the Workers’ Compensation Act. The Committee shall be as between the Employer and the Union, with equal representation, and with each party appointing its own representatives. Representatives of the Union shall be chosen by the Union membership or appointed by the Union. All minutes of the meetings of the Joint Occupational Health & Safety Committee will be recorded in a mutually agreeable format and will be sent to the Union. The Union further agrees to actively pursue with the other Health Care Unions a Joint Union Committee for the purposes of this Article. The Employer agrees to provide or cause to be provided to Employer members of the Joint Occupational Health and Safety Committee adequate training and orientation to the duties and responsibilities of committee members to allow the incumbents to fulfil those duties competently. The Union agrees to provide or cause to be provided to Union members of the Joint Occupational Health and Safety Committee adequate training and orientation to the duties and responsibilities of committee members to allow the incumbents to fulfil those duties competently. Such training and orientation shall take place within six (6) months of taking office.

Time is Money Join Law Insider Premium to draft better contracts faster.